Early MS Biomarkers May Improve Prediction of Long-term Outc

Serum neurofilament light chain and glial fibrillary acidic protein levels can help improve outcome predictions in multiple sclerosis — and are linked to relapse risk after treatment discontinuation.

Related Keywords

Boston , Massachusetts , United States , Ohio , Jeffrey Cohen , Gauruv Bose , Mellen Center , Americas Committee For Treatment , Brigham Multiple Sclerosis Center , Harvard Medical School , Research In Multiple Sclerosis , Ann Romney Center , Neurologic Diseases , Medscape Medical , Americas Committee , Multiple Sclerosis , Brigham Multiple Sclerosis , Extended Disability Status Scale , Medscape Medical News , Cleveland Clinic , Multiple Sclerosis Ms , Us , Biomarker , Iological Marker , Magnetic Resonance Imaging Mri , Magnetic Resonance Imaging , Ri , Maging Magnetic Resonance , Disability , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Secondary Progressive Multiple Sclerosis , Pms , Disease Modifying Therapy , Mt , Activism , Activist , Multiple Sclerosis Treatment , Wts T ,